9999999997-11-011574.txt : 20110615 9999999997-11-011574.hdr.sgml : 20110615 20110615145757 ACCESSION NUMBER: 9999999997-11-011574 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20110615 DATE AS OF CHANGE: 20110615 20110615 20110615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 11912844 BUSINESS ADDRESS: STREET 1: 8001 ARISTA PLACE STREET 2: SUITE 200 CITY: BROOMFIELD STATE: CO ZIP: 80021 BUSINESS PHONE: 720-940-2200 MAIL ADDRESS: STREET 1: 8001 ARISTA PLACE STREET 2: SUITE 200 CITY: BROOMFIELD STATE: CO ZIP: 80021 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 CT ORDER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(#`@;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#$O2VED'0O26UA9V5"+TEM86=E0R]);6%G94E=(#X^+TUE9&EA0F]X6R`P(#`@-C$R M(#2]#4R]$979I8V521T(^/B]486)S+U,O4W1R=6-T4&%R96YT M)R566UOVS80_AX@_X'`ODA`S(JO MDH:B@..\S,62;(X+%%B'P8GM6H`MN;:\MO]^=Y3DF+8H(21A5'@)$2U"N$HHBXG6,56-D$^/H0R&X[`G@MNPQX,;\@PW,NB/;_'9 M\\$])H-/H-EH.![BC7EBWI$^:GQ# M;C^'C`6#W\SM?9A4$#)X>@A[*GA`JY[1$#-H^/3H,$0*"$MJZ]!IB&IS;,PH M$T2+E*:-D(\[G#C'RPR4(4Q=$1XQYG*HC&@2VR(Z]=`M>M29J[GV3+6X+2J: M4M*D."9X2E29'^8W*CW_;9Q8YGV3F MY^^BLS92Y4)0!;I(\99S=\@JV7*_;!\+2ARF<*`OR>SA MD0N;<*J$C>TYL2`WM;&<)[%PN92=XETZ"Y:>8%UZ""ZH5)YR@7*.L8.P%U?^ M_,691`F51U[A2"DZZ4@?=32/$QOS$RQW8I,3;'="M198&(YIR5.J6"WEG[9_ M3NM2PQB'X[NUD%8KPQVMC&(*J[6/P+;RUDB).&5M4BP*AD2(N(WMCP:XGOK` M,RG2S`+H104K%[5PT!:7Y:&(*Z@T+`V&2$EY%[]P+*#"3UKTT;U$/O"_-79&373Y%[,:Y2E))^9%E(U?U`)!@-G:W MG('2+\Y6)L8H6R-<:UM*1M,CZ9QLPIXVUG[;X76+AH'17['^N6RJDT,F"16- M)'1,D<\S\(8*\LH]Z*@E,?[8H!9,"\VIOYF.?Z"&C0I,W!L M%0PR^X&4@M*7N^EL2N8@?E.L2+F80<66P0_DCD7V4L&W!*8I"S(A=]"J%,:X MER?+FS*:6Q#G=K"9N((.L^6X)$S08HE MLEPU`-SJ6L.1PC5LH1\FZ+Z?(7=G`@/:2K0]S-7N,FB[C[':A85-;"7M?+:CN#=GM*,,"P M'LQJ6^^7MGF9EV9=(=E!)_N"L,[0^1C;+F8E,`2AA>V-;F(FEQ<2RQ.L;?TFK()'/23>S;] MMC.,9Z:<9TB$6S+9DM=05]08]I*:^0[H\;58K6;H0N2X;+(D1D\3QGF63Y!- MFS>9X[EK9XOC5M_A@(6PS3;OBZ+K7EBYL[,"$K0>X[YG2[-5(NC.EQG!S$/]E[,).*CF(2C!E66HD;'.\CC9I[!) MCS+;-P5D;7)VDQ53UUJ';D\P6R[;MMJX?KJ!R:,E36]S580]4&C*O>/C_%:K7 MAKFN@.(VVQV28+ZO,V=XE4/WW^@SK4@4:X5A?C-;73SP]ZY<%!NL1E!M?[K< MEL#>+K'ENCB.)8IJ;6.[@]IVGM98@A]._*2T':+44CA^+_&3TO9MH9&"'TS\ MI'2F&YD$A"?MB*W+RP-;E9V(_FI,2TL'DV-XT8 M&64SR%=>]0#.7CZED7#/>QJ9CAT7Q^\VOI'QPM:1\<+6D?'!-I'QPM:1\<$V MD3G$FEY\C3%H-@N#`CELEV]GSJA`-8F9WYR22=QA.;&G$>S8[=8'=CY2.OHJ MCI^\G%+^`U71*H0-"F5N9'-T7!E+T9O;G0O4W5B='EP92]47!E+T9O;G1$97-C7!E+T]B:E-T;2].(#,S+T9IJ"GHVSO)%'$A9-9" MRV32_WQG\I$>$B10@6101;7K!DK6=)`FL-VH&4SVL8[!:IV`FW4*(>NR+;;. M&*V`*W2.-6ANX`[M%DO(]A5"+A9CE,0009$&492J\_[5=I""JA:Q49I%&IK- M(QTM*VRH37([(>T?5(7H^4]4A=C[3U2`^HB^@-^*6` M8`H8IH!B"CBF@&0*6*:`9@IXYH!GCKS'`<\<\,P!SQSPS`'/'/#,?WM.U\QA M/$W^"LTWYH-P*=5+\]*7PLD+>6$OOLZ.PJ5D+TYAI[!3V"GB%'&*.$6<(DX1 MIXA3Q"GB%'&*.D6=HD[1A7+$]2D?OM['X3"=+Z?IX3R.^[>W:=@]G6[<63K+HN6*^E+Q=X.>'NI&$J)/40= MH(4]_'9'NRQO_RE``CWHPP"&,((QI)!!#@64,($(%=0PA1G,80$-+&$%:]C` M%G86)5X]>_60/KC_#',-"F5N9'-TF4@-#